The grant will be used to fund Felix's machine-learning approach for engineering bacteriophage as a novel treatment for drug-resistant bacterial infections.

The funds will support Felix's efforts in engineering phage for improved efficacy and utility, starting with proof-of-concept work in Pseudomonas aeruginosa, a pathogen of high clinical need, the company said.